# Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

> **NCT03311841** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (actual)

## Conditions studied

- Renal Insufficiency

## Interventions

- **DRUG:** Midazolam oral solution
- **DRUG:** Dabigatran and pitavastatin oral solution
- **DRUG:** Atorvastatin and rosuvastatin oral solution
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT03311841
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2018-08-02
- **Final completion:** 2018-08-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03311841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03311841, "Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03311841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*